## WEATTUST

# Provider News July 2020



## COVID-19

Due to the COVID-19 pandemic, the healthcare industry has had to make dramatic changes in the delivery of healthcare. As we continue to adjust to the current needs of our state, community, members, and your patients, we would like to maintain open communication with our provider partners and work together to meet the requirements of this evolving environment. We strive for the best member experience in collaboration with our providers.

During this unprecedented situation, WEA Trust will continue to provide you with pertinent information surrounding our business continuity plan as well as additional helpful information and resources.

#### **BUSINESS CONTINUITY**

To ensure the safety of our employees, the majority of WEA Trust employees are working remotely and continue to respond to all of our member and provider inquiries. Providers are encouraged to email inquiries to **CustomerService@WEAtrust.com**, as well as through our Maddy Portal, **www.MaddyPortal.com**.

#### PROVIDER FAQ

A Provider FAQ that addresses concerns and questions you may have in the delivery of care has been placed on our website. As new information is available this FAQ will be updated: www.WEAtrust.com/providers/provider-covid-19.

The circumstances surrounding COVID-19 are rapidly changing, and we continue to monitor its progression and the guidance being issued by state, federal and global healthcare agencies. We will continue to issue additional

communications and updates as matters change. We are committed to keeping you and our members informed while providing necessary information as it becomes available.

WEATrust staff are working hard to support our providers and we thank all of the healthcare staff working tirelessly for those in need. Your dedication and commitment are truly appreciated.

## MEDICAL MANAGEMENT

## **Preauthorization Updates**

#### INFERIOR TURBINATE ABLATION

Effective April 1, 2020, Inferior Turbinate Ablation no longer requires preauthorization when performed intramurally or superficially. This applies to CPT Codes 30801 and 30802.

## **PHARMACY**

## Medintegrate - Medical Drug Copay Assistance Program

Effective June 1, 2020, our medical specialty drug program is enhancing member access to copay assistance to help reduce medication costs. This is intended to lower the upfront cost to members. Our medical specialty drug copay assistance program is managed in partnership between MedImpact and Archimedes who offer the Medintegrate Medical Copay Assistance program.

An added benefit is many of the drug manufacturer programs will reimburse the member contribution directly to your office. This may offer you quicker reimbursement than waiting for payment by the member.

### WHAT DOES THIS MEAN TO YOU?

- Your office can continue to purchase and bill WEA Trust for the specialty medication(s) administered in your office, just as you have been doing.
- For members who have an existing authorization, Archimedes will identify and notify you of members who should be enrolled in this program.
- For new authorizations, the member will be enrolled in the program at the time of approval and you will be notified as well.
- You will receive information to assist the member to enroll in the copay assistance program and a copy of the member's letter.

#### WHAT HAPPENS NEXT?

An Archimedes Member Service Coordinator will contact you as members are identified for this program. Our goal is to support you in member enrollment and ensure a smooth transition. If you do not receive a phone call from Archimedes, please call Archimedes at **888.533.6096** and they will assist you with any questions you have.

## **Preauthorization Updates**

#### **PEGFILGRASTIM**

Effective May 15, 2020, Fulphila (Q5108), Udenyca (Q5111) and Ziextenzo (J3590) are the preferred biosimilars to Neulasta (J2505) and will require preauthorization.

Neulasta (J2505) and Neulasta OnPro (J2505) are non-preferred and will require preauthorization to be considered for use.

## **Exclusion Updates**

#### **NEXLETOL**

Nexletol is a new FDA approved drug that will be excluded to determine efficacy and coverage policy.

## PHARMACOGENOMIC TESTING

Effective March 1, 2020, pharmacogenomic testing delivered by a provider system will no longer be covered.

All pharmacogenomic testing will need to be performed through the Personalized Medicine program offered by MedImpact. For more information about this program, you may visit their website at www.medimpact.com/members/resources.

If you have any further questions, please contact MedImpact directly at **858.790.3021** or via email at **personalizedmedicine@medimpact.com**.

## **COLOGUARD**

WEA Trust is partnering with Cologuard to offer free, at home colorectal cancer screening for members.

The 4 top reasons to screen for colorectal cancer today:

- Colorectal cancer is the 2nd leading cause of cancerrelated death. <sup>1</sup>
- When caught in its early stages, colorectal cancer is more treatable in 90% of people. <sup>2</sup>
- Colorectal cancer is on the rise in middle-aged and older adults.
- At least 70% of people with colorectal cancer have no family history.

Members who are 50 to 75 years of age\* can talk to their healthcare provider about using Cologuard as their colorectal screening option. A doctor must provide a prescription for the screening kit for the test to be delivered.

Providers can receive the prescription form on our website at www.WEAtrust.com/Cologuard.



#### **COLOGUARD IS:**

Noninvasive

An easy option that you can use in the privacy of your own home.

Convenient

Cologuard is delivered to your doorstep and picked up when you are done.

Effective

Cologuard detects altered DNA and blood in stool to find 92% of colorectal cancers.

Affordable

Offered for free to eligible members.

#### QUESTIONS?

Visit our website at www.WEAtrust.com/Cologuard.

\*Based on health history; not all members may be appropriate candidates for Cologuard. Members should talk to their doctor for more information.

Sources

- 1 American Cancer Society. Key statistics for colorectal cancer. https://www.cancer.org/cancer/colon-rectal-cancer/about/key-statistics.html. Last revised January 2019. Accessed January 8, 2020.
- 2 National Cancer Institute. SEER Cancer stat facts: colorectal cancer. https://seer.cancer.gov/statfacts/html/colorect.html. Accessed January 8, 2020
- 3 Siegel RL, Fedewa SA, Anderson WF, et al. Colorectal cancer incidence patterns in the United States, 1974–2013. J Natl Cancer Inst. 2017;109(8). 10.1093/jnci/jw322.
- 4 Patel SG, Ahnen DJ. Familial colon cancer syndromes: an update of a rapidly evolving field. Curr Gastroenterol Rep. 2012;14(5):428-438.
- 5 Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014;370(14):1287–1297.

## **CODE COVERAGE**

#### MULTIPLE SURGERY REIMBURSEMENT POLICY

Effective May 1, 2020, WEA Trust updated our reimbursement policy regarding multiple surgery reductions when three or more surgical procedures are performed in the same session to align with Medicare. This policy will apply to Modifier 51 and will affect professional claims with a date of service after May 1, 2020.

The reimbursement will be as follows based on the contracted allowed amount:

- Procedure with the Highest Contracted Rate or Base Maximum Amount Payable: 100%
- Procedure with the Second Highest Contracted Rate or Base Maximum Amount Payable: 50%
- · All other Procedures: 25%

#### **CONSULTATION CODES - COVERAGE UPDATE**

As of January 1, 2010, Medicare discontinued reimbursement for Consultation Codes. Medicare required providers to bill the appropriate Evaluation & Management codes when the services were being performed in a clinic setting. If the setting is a hospital or skilled nursing facility, then the appropriate hospital or nursing visit codes should be utilized.

Effective June 1, 2020, to align with Medicare policies, WEATrustwill discontinue reimbursement for consultation codes. If consultation codes are submitted the service will deny as "provider responsibility" and the member may not be billed.

Pathology consultations are exempt from this policy and will continue to be covered utilizing the appropriate pathology consultation codes.

#### **DEVICE-DEPENDENT PROCEDURES**

As a reminder, WEA Trust follows the guidelines from the Centers for Medicare and Medicaid Services (CMS) regarding device-dependent procedures. Reimbursement of a device-dependent procedure requires that a device be submitted on the same claim for the same date of service. As of January 1, 2015, the Integrated Outpatient Code Editor (IOCE) also supports this requirement.

## **REMINDERS**

#### BREAST PUMPS AND SUPPLIES

WEA Trust will cover manual or electric breast pumps. Hospital grade and hands-free breast pumps are not covered.

Replacement bottles and other supplies for covered breast pumps are not covered.

## **PROVIDER CHANGES**


Network providers are responsible for notifying WEA Trust of any updates to their provider organization, business practice, or practitioners. Please use our Provider Update Form, found on our website at **WEAtrust.com/provider/provider-forms**.

Please provide a minimum of 30 days prior notice for any such changes, including but not limited to:

- · Change in ownership, operations, or incorporation status
- $\cdot$  Change in Tax ID number or legal business name
- · Acquisition of other medical practice or entity
- · Change in accreditation, licensure or eligibility status
- · Change in billing or other contact information
- · Change in service location
- · Practitioner joining or leaving your organization
- · Change in practitioner name, credentials, or specialty

## **CREDENTIALING**

Contracted providers must complete the credentialing process and receive approval for network participation prior to rendering services to WEA Trust members. Services provided before the successful completion of the credentialing process will be denied and may not be billed to the member.



## Let's Keep in Touch!

Stay updated with WEA Trust news and reminders.

Follow us on social media.
Stay connected with us on Facebook.

FACEBOOK.COM/WEATRUST





## Go to weatrust.com/providers

### TO SIGN UP TO RECEIVE THIS VIA EMAIL

0604.672.008

Provider Services

1156.295.800 Nora Moses - Manager of Credentialing

4279.139.809

Chris Auger - Provider Contract Manager

5099.199.809

Lisa Hankel - Provider Contract Manager

9999.199.809

Traci Schaefer - Provider Relations Manager

2979.199.809

& Network Management Joe Weyer - Director of Provider Contracting

9799.199.809

Tim Bartholow, M.D. - Chief Medical Officer

Provider Network Contacts

WEATING